Case report: Minimal manifestations of mucous membrane pemphigoid in a young adult

Franziska Schauer*, Federica Casetti and Dimitra Kiritsi

Department of Dermatology, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

A male patient presented to our department at the age of 23 suffering from recurrent painful erosions in the urethral outlet area. In closer clinical examination gingival erosions, primarily around the teeth were identified as well. Indirect immunofluorescence on salt split skin with epidermal IgG deposition and positive anti-BP230 IgG ELISA diagnostics hinted toward the presence of mucous membrane pemphigoid (MMP). Direct immunofluorescence from oral mucosa confirmed the diagnosis. MMP in young adulthood is an underdiagnosed disease and latency of diagnosis was around 4 years in our case. Treatment with systemic glucocorticosteroids and dapsone led to clinical remission, prohibiting the development of MMP manifestations in further organs and complications associated with the disease, e.g., scar formation and miction problems.

KEYWORDS
blistering disorder, skin fragility, urethral erosion, autoimmune disease, hemidesmosome, BP230

Introduction
Mucous membrane pemphigoid (MMP) is an autoantibody-mediated subepidermal blistering disease with predominant involvement of mucous membranes and tendency of scarring (1). The scarring can interfere with the patients’ normal functions, e.g., vision, food intake, miction, and sexual intercourse, thus have a serious impact for their quality of life (2). Larynx involvement might even be fatal due to breathing impairment (3). The diagnosis is based on clinical findings and the detection of autoantibodies against known autoantigens at the basement membrane, primarily BP180, BP230, laminin 332, and collagen VII (4). Direct and/or indirect immunofluorescence diagnostics, as well as ELISA for the specific proteins and immunoblotting are essential for correct diagnosis (4). We here present a male patient with only few erosions on his gingiva and urethra and minimal inflammatory signs of the disease, who was diagnosed having an MMP and responded to immunosuppressive treatment.
Schauer et al. 10.3389/fmed.2022.1052145

FIGURE 1
Clinical picture. Discrete swelling and erosions (highlighted by arrows) around the gingival fringes of the upper (A) and lower tooth space (B), as well as a painful ulcer at the urethral entrance were identified at initial presentation (C). Inconspicuous mucosal findings of the upper gingiva (D) and lower gingiva (E) and urethral outlet (F) followed initiation of therapy with prednisolone combined with dapsone.

Case report

A 23-year-old male patient from middle Europe suffered from recurrent, painful erosions in the urethral outlet area since around 4 years. Due to congenital hypospadias in the urethral area, he was regularly examined by urologists. The persistence of the mucosal lesions resulted in referral to our Dermatology department. Clinical examination showed an ulcer on the urethral outlet area, but also few erosions on the gingiva, which mimicked a mild gingivitis (Figure 1). He was not hampered by the gingival lesions in his everyday life. He was otherwise healthy, without any medication. Sexually transmitted disorders had been ruled out.

We initiated specific diagnostics for autoimmune blistering disorders. The indirect immunofluorescence on salt split skin showed epidermal IgG reactivity at blister roof, compatible with an active pemphigoid disorder (Figure 2A). In addition, an isolated positive BP230 ELISA at 85 U/ml (cut off > 9 U/ml) was identified, while NC16A BP180 ELISA was negative (MBL, Nagoya, Japan). The subsequently performed analysis from a biopsy of unaffected buccal mucosa revealed IgG and C3 deposition at the dermal-epidermal junction in the direct immunofluorescence (Figures 2B–D). Immunoblotting analysis using human epidermal extract as substrate showed IgG immunoreactivity with BP230 and slightly also collagen VII (Figure 2F). IgA autoantibodies did not react in any analysis. Histological examination taken from buccal mucosa yielded a hyperplastic, non-keratinizing, mucosal epithelium without cleavage (Figure 2E). No inflammatory infiltrate was detectable in the dermis nor evidence for PAS-positive fungal elements were identified. The patient was treated with oral prednisolone 0.3 mg/kg body weight and oral dapsone 50 mg/day (0.8 mg/kg body weight). Lesions of the patients healed with topical tacrolimus 0.1% ointment for the urethral area and triamcinolone acetonide 0.1% cream for the gingiva after 8 weeks.

Discussion

Mucous membrane pemphigoid (MMP) is a chronic and usually blistering disorder with about 2/million inhabitants/year being diagnosed in central Europe (5). In general, MMP can affect multiple mucosal sites, but oral mucosa is most frequently involved, followed by ocular, anogenital, nasopharyngeal, laryngeal, and esophageal sides (5, 6). It is considered a disease of the elderly with disease onset typically within the 6th decade of life (7). In young adulthood it is rarely described and sometimes associated with trauma (8). On the other hand, vulvar or urethral MMP has been described in children as well, while the genital area appears to be more commonly affected than other mucosal surfaces at young age (9). Altogether, less than 20 cases of isolated genital MMP have been reported in the literature, notably with either children or geriatric patients being affected.
FIGURE 2
Direct immunfluorescence (DIF) of buccal mucosa shows linear IgG and C3 depositions at basement membrane zone, each indicated by arrows (A,B). DIF found no reactivity for IgA (C). Indirect immunofluorescence on 1M split human skin using patient’s serum shows epidermal staining of IgG (D). Histopathology of buccal mucosa of the patient (hematoxylin-eosin stain, 200x magnification) (E). Immunoblot analysis revealed IgG autoantibodies against BP230 and slightly also against collagen VII (F).

(10–13). The fact that more cases are being reported in recent years is likely due to increased awareness and easier access to serological testing (10–12). The latency to diagnosis in our case was approximately 4 years, which is to be expected for such mild disease manifestations. Hopefully, the time between disease manifestation and diagnosis can be shortened as more cases are presented.

The gingival lesions as in our case could be misinterpreted as periodontitis. Additionally, our patient had suffered with congenital hypospadias with complicating development of urethral fistula after surgical correction 18 years ago. It remains unclear whether the latter may have already been part of the autoimmune bullous disease activity or actually the trauma initiated the development of autoantigens.

According to literature NC16A BP180 is the most frequent autoantigen in MMP patients followed by reactivity against the LAD-1 ectodomain and laminin 332 (14). Reactivity against BP230 as in our patients is only found in a minority of patients (14–16), while their pathogenetical relevance is disputed, since BP230 is an intracellular antigen (17). Nonetheless, we here present a case with genital MMP involvement due to primarily BP230 autoantibodies, with no similar cases described so far. Serological tests are frequently negative at initial MMP disease stages, thus repeated sampling is required when clinical suspicion for MMP exists (18).

Mucous membrane pemphigoid (MMP) is feared for its treatment refractory course. Our patient responded well to the combination of low dose prednisolone with dapsone, but
relapsed mildly when prednisolone was tapered. Instead of dapsone, classical immunosuppressants as mycophenolate or azathioprin can be employed, while rituximab is considered an off-label ultima ratio, especially in severely scarring courses (19–21). Finally, other approaches with intravenous immunoglobulins or omalizumab have been reported to be useful as well (22, 23).

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Human Ethics Committee University of Freiburg (reference no. 235/15). Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

References

1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. (2013) 381:320–32. doi: 10.1016/S0140-6736(12)61440-4
2. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. (2012) 66:479–85. doi: 10.1016/j.jaad.2011.06.032
3. Barmatz S, Banai A, Eremenko R, Neiderman NNC, Wasserzug O, Sprecher E, et al. Laryngeal pemphigoid evolution and response to treatment. J Voice. (2021) 30:892-1997:00033–3. doi: 10.1016/j.jvoice.2021.01.012
4. Rashid H, Lambert A, Borradori L, Alberti-Violetti S, Barry RJ, Caproni M, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - Part I. J Eur Acad Dermatol Venereol. (2021) 35:1750–64. doi: 10.1111/jdv.17397
5. Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev. (2022) 21:103036. doi: 10.1016/j.autrev.2022.103036
6. Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allerg Immunol. (2018) 54:26–51. doi: 10.1007/s12016-017-5633-4
7. Lee J, Seiffert-Sinha K, Attwood K, Sinha AA. A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a Scottish-based registry. Front Immunol. (2019) 10:2219. doi: 10.3389/fimmu.2019.02219
8. Sambharra D, Lee JH, Pantanelli SM. Atypical case of mucous membrane pemphigoid in a 26-year-old man. BMJ Case Rep. (2018) 2018:bcr2018225872. doi: 10.1136/bcr-2018-225872
9. Rodriguez Baisi K, Wentworth A, Chattah AI, DiCaudo DJ, Mangold A, Nelson SA, et al. A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa. Pediatr Dermatol. (2021) 38:904-7. doi: 10.1111/pde.14627
10. Orfaly VE, Morrison L, Fett N, Greiling TM. Mucous membrane pemphigoid involving the urethra: a case series. J Eur Acad Dermatol Venereol. (2020) 34:e310–1. doi: 10.1111/jdv.16217
11. Joly E, Seta V, Plantier F, Dupin N, Chanal J. Localized genital mucous membrane pemphigoid of the penis: notes on two cases. Ann Dermatol Venereol. (2021) 148:292–3. doi: 10.1016/j.annder.2021.02.005
12. Boch K, Ludwig RJ, Zillikens D, Schmidt E. Penile mucous membrane pemphigoid. J Dermatol. (2020) 37:727–9. doi: 10.1111/1346-8138.13361
13. Belzile E, Funaro D, Powell J. Localized vulvar bullous pemphigoid of childhood: a rare cause of persistent vulvar erosions in children. Pediatr Dermatol. (2019) 36:349–51. doi: 10.1111/pde.13771
14. van Beek, N, Kridin K, Bühler E, Kochan AS, Ständer S, Ludwig RJ, et al. Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol. (2022) 158:84–89. doi: 10.1001/jamadermatol.2021.4773
15. Inoue T, Yagami A, Iwata Y, Ishii N, Hashimoto T, Matsunaga K. Mucous membrane pemphigoid reactive only with BP230. J Am Acad Dermatol. (2016) 74:1228–9. doi: 10.1016/j.jaad.2017.05.016
16. Yoshimoto N, Ujiie I, Inamura E, Natsuga K, Nishie W, Shimizu H, et al. A case of mucous membrane pemphigoid with anti-BP230 autoantibodies. Ann Dermatol Venereol. (2020) 148:202–3. doi: 10.1016/j.annder.2021.02.005
17. Shimano I, Nitz JM, Zillikens D. Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid. J Am Acad Dermatol. (2017) 77:700–5.e3. doi: 10.1016/j.jaad.2017.05.016
18. Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid

Author contributions

FS, FC, and DK had full access to all of the data in the study. FS and DK took responsibility for the integrity of the data and the accuracy of data analysis. All authors read, revised, and approved the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
20. Baffa ME, Corrà A, Maglie R, Mariotti EB, Montefusco F, Pipitò C, et al. Rituximab in mucous membrane pemphigoid: a monocentric retrospective study in 10 patients with severe/refractory disease. J Clin Med. (2022) 11:4102. doi: 10.3390/jcm11144102

21. Bohelay G, Alexandre M, Le Roux-Villet C, Sibon I, Doan S, Soued I, et al. Rituximab therapy for mucous membrane pemphigoid: a retrospective monocentric study with long-term follow-up in 109 patients. Front Immunol. (2022) 13:915205. doi: 10.3389/fimmu.2022.915205

22. Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. (2019) 10:1090. doi: 10.3389/fimmu.2019.01090

23. Alexandre M, Bohelay G, Gille T, Le Roux-Villet C, Soued I, Morin F, et al. Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients. Front Immunol. (2022) 13:874108. doi: 10.3389/fimmu.2022.874108